Company / Current Assets
ADMA Biologics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$466.5M
FY2025
5-year range
$208.7M / $466.5M
FY2021-FY2025
Trend
+40.8%
vs FY2024
Sector context
#122 of 213
Health Care
What the data says
At $467M, ADMA Biologics, Inc.'s current assets ranks #122 of 213 in the Health Care sector. Current Assets has fluctuated over the past 10 years, ranging from $22M in FY2016 to $467M in FY2025.
Based on SEC 10-K filings.
$467M in FY2025 with a 5-year CAGR of +24.9%.
Improved from $257M to $467M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +19.9%
- 5-Year CAGR
- +24.9%
- 10-Year CAGR
- -
Sector benchmark
#122 of 213 in Health CareTop 57% of 213This company $466.5M Sector average $2.5B
▼
-81.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.9%, indicating consistent growth.
- In FY2025, current assets increased 40.8% year-over-year.
- Ranks #122 out of 213 companies in the Health Care sector.
- Lowest current assets in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $466.5M | +40.8% |
| FY2024 | $331.4M | +28.9% |
| FY2023 | $257.0M | -5.0% |
| FY2022 | $270.4M | +29.5% |
| FY2021 | $208.7M | +35.8% |
| FY2020 | $153.7M | +79.1% |
| FY2019 | $85.8M | +92.7% |
| FY2018 | $44.5M | -29.5% |
| FY2017 | $63.2M | +191.7% |
| FY2016 | $21.7M | +1.7% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026